Project Oncology®

What do we need to know about the Microscaled Proteogenomic Analysis method and the potential impacts of providing detailed tissue analyses from single-core needle biopsies? Here to talk about this new diagnostic tool for breast cancer is Dr. Matthew Ellis, Director of the Lester and Sue Smith Breast Center at Baylor College of Medicine.

Join Dr. Erika Hamilton as she reviews the molecular subtypes of early-stage breast cancer and the shift towards personalized approaches to treatment with targeted therapies.

Join Dr. Erika Hamilton as she reviews the molecular subtypes of early-stage breast cancer and the shift towards personalized approaches to treatment with targeted therapies.

What is the role of autoantibodies in breast cancer detection? Dr. Pallav Mehta, the Director of Integrative Oncology and Practice Development at the MD Anderson Cancer Center at Cooper University Health Care, shares the latest research on autoantibodies as potential biomarkers in the early detection of breast cancer?

With only 3% of practicing oncologists identifying as Black, and less than 5% identifying as Latinx, how can we ensure these patient populations are equally represented in medical practice? Dr. Jacob Sands meets with ASCO’s current President, Dr. Lori Pierce, a Professor of Radiation Oncology and Vice Provost for Academic and Faculty Affairs at the University of Michigan, to discuss ASCO’s plan to increase quality in cancer care and research.

Lung cancer remains the most common cancer in the United States and Europe and second most common in Japan. Of patients with non-small cell lung cancer (NSCLC), approximately 3% to 4% have tumors that harbor MET gene aberrations including MET exon 14 skipping mutations. These patients have an even worse prognosis than others with NSCLC, and early diagnosis and targeted therapies are essential. Join us as Dr. Paul Paik and Dr. Jyoti Patel discuss the value that liquid biopsy brings to patients with NSCLC, specifically those with MET exon 14 skipping mutations.

What are some of the clinical considerations for RET-rearranged non-small cell lung cancer? Dr. Ross Camidge, Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, briefly discusses the guidelines and benefits of therapy recommended for non-small cell lung cancer by the National Comprehensive Cancer Network.

Lung cancer screening is one of the most critical components of reducing cancer mortality rates. Dr. Andrea McKee, Chair Emeritus in Radiation Oncology and Director of the Lung Screening Program at Lahey Hospital and Medical Center, joins Dr. Jacob Sands to discuss updates in lung screening.

How can a lung screening program enhance the quality of care for patients with lung cancer? Dr. Andrea McKee, Chair Emeritus in Radiation Oncology and Director of the Lung Screening Program at Lahey Hospital and Medical Center, shares how she and her colleagues designed this program at Lahey Hospital and Medical Center.

What’s recent research saying about the use of tomosynthesis versus conventional 2D digital mammography to screen for breast cancer? Find out with Dr. Manisha Bahl, a breast imaging radiologist and Assistant Professor of Radiology at Harvard Medical Center.